Vanda Pharmaceuticals Inc.

03/10/2026 | Press release | Distributed by Public on 03/10/2026 14:47

Regulation FD Disclosure (Form 8-K)

Item 7.01. Regulation FD Disclosure.
On March 10, 2026, Mihael Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of the Board of Vanda Pharmaceuticals Inc. ("Vanda"), appeared on Mornings with Maria on Fox Business and discussed Vanda's pricing and commercial strategy for its drug, NEREUSTM, which was recently approved by the U.S. Food and Drug Administration for the prevention of vomiting induced by motion. During the interview on Fox Business, Dr. Polymeropoulos disclosed that Vanda is developing NEREUSRXTM, which will be a direct-to-consumer channel for access to NEREUSTM. Dr. Polymeropoulos then indicated that NEREUSTMwill be available in the next couple of months. The full interview can be seen here: https://www.foxbusiness.com/video/6390680373112.
The information furnished pursuant to this Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Vanda Pharmaceuticals Inc. published this content on March 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 10, 2026 at 20:48 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]